New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Saturday, Nov 21, 2026
Export SCTX’s income statement to Excel — free account
Scribe Therapeutics Inc.
SCTXScribe Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $51.2 million.
12.07
1.15
−8.70%
After hours trading: 12.00, down 0.58%, last trade Fri 7:39pm Eastern.
Follow SCTX
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | — |
+2 more quarters Free account |
P/S ratio |
10.31 | 1.84 | 1.84 | — | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — | |
P/Operating CF |
(23.72) | (4.75) | (4.75) | — | |
P/B ratio |
2.13 | 0.00 | 0.00 | — | |
Price to Tangible BV |
2.13 | 0.00 | 0.00 | — | |
EV/Sales |
3.58 | 0.36 | 0.36 | — | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | — | |
EV/Operating CF |
0.00 | 0.00 | 0.00 | — | |
EV/FCF |
0.00 | 0.00 | 0.00 | — | |
Quick Ratio |
4.62 | 0.56 | — | 0.94 | |
Current Ratio |
4.72 | 0.57 | — | 0.97 | |
Net Debt/EBITDA |
17.26 | 4.58 | — | — | |
Debt/Assets |
0.00% | 0.00% | — | 0.00% | |
Debt/Equity |
0.00 | 0.00 | — | 0.00 | |
Operating CF/Net income |
1.14 | — | — | — | |
Capex/Depreciation |
(0.02) | — | — | — | |
Interest Coverage |
— | (34.04) | — | — | |
Research and Development Expense of Revenue |
504.83% | 460.01% | — | — | |
Selling, General and Administrative Expense of Revenue |
259.11% | 129.82% | — | — | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | — | 0.00 | |
Share Based Compensation of Revenue |
74.27% | — | — | — | |
Graham Net Nets |
0.44 | (1.07) | (1.07) | — | |
Graham Number |
0.00 | 140.31 | 0.00 | — | |
Earnings Yield |
(52.93%) | (60.70%) | (60.70%) | — | |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% | — | |
Revenue per Share |
0.11 | 0.77 | 0.91 | — | |
Operating CF per Share |
(0.78) | — | — | — | |
Capex per Share |
0.00 | — | — | — | |
Free Cash Flow per Share |
(0.78) | — | — | — | |
Cash per Share |
12.02 | 17.37 | — | — | |
Shareholders Equity per Share |
8.63 | (17.97) | — | — | |
Interest Debt per Share |
0.00 | 0.00 | — | — | |
Book value per Share |
8.63 | (17.97) | — | — | |
Free Cash Flow |
(11.26) | — | — | — | |
Working Capital |
140.96 | (33.59) | — | (2.12) | |
Capital Expenditures |
(0.01) | — | — | — | |
Net Current Asset Value |
116.13 | (57.31) | — | (34.35) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | — | |
Capex to Sales |
0.01 | — | — | — | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — |
Columns are period end dates · fundamentals updated Nov 18, 2026